LAVA Therapeutics NV (LVTX) Peer Comparison
$1.74
$0.00 (0.00%)As on 28-Nov-2025 09:30EDT
Market cap
$46 Mln
Revenue (TTM)
$5 Mln
P/E Ratio
--
P/B Ratio
3.6
Div. Yield
0 %
Edit
| LAVA Therapeutics NV (LVTX) | Qiagen N.V. - ADR | Merus N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
46 | 9,272 | 6,826 | 2,480 | 3,380 |
Revenue ($ Mln) |
5 | 2,100 | 51 | -- | 19 |
Net Profit ($ Mln) |
-23.28 | 409.32 | -334.90 | -171.57 | -252.21 |
Net Margin (%) |
-466.45 | 19.49 | -654.43 | -- | -1,350.73 |
RoE (%) |
-121.01 | 11.47 | -53.25 | -59.98 | -96.46 |
Price to Earnings |
-- | 22.68 | -- | -- | -- |
Price-To-Book |
3.61 | 2.74 | 8.81 | 7.40 | 10.60 |
Cashflow ($ Mln)
| LAVA Therapeutics NV (LVTX) | Qiagen N.V. - ADR | Merus N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-19.54 | 673.55 | -185.84 | -120.13 | -182.73 |
|
Cash Flow from Investing Activities
|
12.48 | -249.23 | -220.22 | -0.54 | 162.97 |
|
Cash from Financing Activities
|
-0.57 | -422.90 | 494.01 | 2.68 | -59.49 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| LAVA Therapeutics NV (LVTX) | Qiagen N.V. - ADR | Merus N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-55.49 | 1.57 | -40.50 | -41.11 | -118.19 |
|
ROE (%)
|
-121.01 | 2.27 | -53.25 | -41.18 | -238.46 |
|
ROA (%)
|
-30.09 | 1.42 | -29.28 | -38.90 | -34.51 |
|
EBIT Margin (%)
|
-442.28 | -- | -636.76 | -- | -- |
|
Net Margin (%)
|
-466.45 | 4.23 | -654.43 | -- | -883.35 |
|
Cash Profit Margin (%)
|
0.00 | -- | 0.00 | -- | -- |
Growth Ratios
| LAVA Therapeutics NV (LVTX) | Qiagen N.V. - ADR | Merus N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-34.11 | 0.01 | 55.90 | -- | 0.71 |
|
EBIT Growth (%)
|
5.81 | -- | -54.14 | -- | -- |
|
Net Profit Growth (%)
|
15.98 | -75.51 | -50.28 | -33.06 | 22.34 |
|
EPS Growth (%)
|
16.20 | -0.75 | -31.75 | -0.28 | 0.24 |
|
Book Value Growth (%)
|
-61.63 | -- | -15.15 | -- | -- |
Valuation Ratios
| LAVA Therapeutics NV (LVTX) | Qiagen N.V. - ADR | Merus N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-1.02 | 116.14 | -13.92 | -7.77 | -3.60 |
|
Price / Book Value
|
0.92 | 2.72 | 4.47 | 3.89 | -127.74 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
1.95 | 27.60 | -9.10 | -5.24 | -3.49 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| LAVA Therapeutics NV (LVTX) | Qiagen N.V. - ADR | Merus N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.45 | 0.00 | 0.00 | -9.78 |
|
Short term debt to equity ratio
|
0.00 | 0.02 | 0.00 | 0.00 | -0.53 |
|
Current Ratio
|
12.27 | 3.61 | 7.97 | 12.60 | 9.74 |
|
Quick Ratio
|
12.27 | 3.09 | 7.97 | 27.27 | 9.74 |
|
Interest Coverage
|
-34.08 | 3.76 | -8.53 | -4,977.62 | -2.72 |
Operating Efficiency Ratios
| LAVA Therapeutics NV (LVTX) | Qiagen N.V. - ADR | Merus N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
0.00 | 23.20 | 37.93 | -- | 21.69 |
|
Asset Turnover
|
0.06 | 0.34 | 0.04 | 0.00 | 0.04 |
|
Receivable days
|
51.79 | 89.98 | 45.51 | -- | 67.84 |
|
Inventory Days
|
-- | 122.42 | 0.00 | 2,694.23 | 119.82 |
|
Payable days
|
2,803.12 | 30.25 | 73.03 | 6,434.88 | 137.64 |
|
Cash Conversion Cycle
|
-- | 182.15 | -27.52 | -- | 50.01 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
